SUNNYVALE, CA, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) - Graid Technology today announced the successful completion of its agreement with Intel Corporation to license the rights to market, sell, and develop Intel® Virtual RAID on CPU (Intel® VROC). The successful completion of this transaction marks a significant milestone that accelerates Graid Technology's progress toward profitable growth and delivering on its vision for the future of enterprise storage.Graid Technology Finalizes Intel® VROC Licensing Agreement, Expanding Leadership in Enterprise Storage Solutions"This agreement represents an exciting new chapter for Graid Technology and for the global ecosystem that relies on Intel® VROC," said Leander Yu, CEO of Graid Technology. "Finalizing the deal allows us to ensure long term continuity for existing customers while also accelerating innovation and value creation across the enterprise storage market."Since the initial announcement, Graid Technology has engaged in productive discussions with many VROC customers, OEMs, and channel partners who have expressed strong support and enthusiasm for the transition."Customer response has been overwhelmingly positive," added Thomas Paquette, Sr. Vice President and GM, Americas & EMEA at Graid Technology. "Partners and system builders see this transition as a win win; protecting their current investments in Intel® VROC while benefiting from Graid Technology's focus, agility, and commitment to high performance storage innovation."Under the terms of the agreement, Graid Technology has assumed responsibility for Intel® VROC customer support and development pipeline, ensuring uninterrupted service and expanding collaboration opportunities across new storage and data infrastructure markets. At this time, Graid Technology has not established a roadmap for new feature enhancements to Intel® VROC, but the team is actively listening to customer feedback and prioritizing their ongoing needs.For more information about Intel® VROC and Graid Technology's enterprise storage solutions, visit https://graidtech.com/vroc.Media Inquiries:Andrea EakenGraid Technology Sr. Director of Marketing, Americas & EMEAandrea.eaken@graidtech.comContact InformationAndrea EakenSenior Director of Marketing, Americas & EMEAandrea.eaken@graidtech.com949-742-9928SOURCE: Graid Technology Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

KEY HIGHLIGHTS-  Revenue increased 7.7% year-on-year to HK$429.6 million-  Gross profit rose 23.2% to HK$253.6 million-  Profit attributable to equity shareholders increased 20.0% to HK$115.0 million-  Declared an interim dividend of HK9.75 cents per share-  Ho Chai Kung and Po Chai Pills achieved steady growth supported by strong marketing and brand execution- Cross-border e-commerce and concentrated Chinese medicine granules (CCMG) businesses remained resilient and contributed to stable performanceHONG KONG, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) – JBM (Healthcare) Limited (“JBM Healthcare” or the “Company”, Stock Code: 2161, together with its subsidiaries, the “Group”), a leading branded healthcare products marketer and distributor in Hong Kong, today announced its interim results for the six months ended 30 September 2025 (“FY2026 Interim” or the “Reporting Period”).Despite a challenging retail environment, JBM Healthcare delivered moderate growth, with revenue increasing by 7.7% to HK$429.6 million and profit attributable to equity shareholders rising by 20.0% to HK$115.0 million during the Reporting Period. The solid performance was underpinned by the strength of its flagship proprietary brands, diversified product portfolio, and disciplined execution. The Group continued to enhance brand equity and expand market reach through integrated marketing, e-commerce expansion, and strategic engagement initiatives across Hong Kong and the Greater Bay Area.Resilient Performance across Core SegmentsDuring the Reporting Period, the Branded Medicines segment achieved solid growth, led by the sustained momentum of Ho Chai Kung. Building on its reputation as a trusted over-the-counter remedy for pain and fever, the brand further strengthened its market presence through a series of high-impact marketing initiatives.Television advertising featuring brand ambassador Hins Cheung enhanced brand awareness and consumer engagement, while strategic sponsorships and event partnerships broadened audience reach. The brand also gained strong visibility through its participation in large-scale televised events, effectively connecting with both middle-aged and younger consumers.The Proprietary Chinese Medicines segment recorded notable growth, led by Po Chai Pills and supported by the CCMG business.During the period, Po Chai Pills launched its innovative “tear-and-take” sachet pack designed for convenient, on-the-go use. A lively TV commercial featuring Louis Koo, Tony Wu , and Bonnie Wong captured strong public attention, blending nostalgic charm with modern visuals and achieving millions of online views within weeks of launch, adding momentum for the brand. Complemented by community campaigns, youth outreach, and large-scale outdoor visibility, these initiatives further strengthened Po Chai Pills’ relevance across generations.The Health and Wellness Products segment recorded a moderate decline due to the rationalisation of certain products, partially offset by the solid and steady growth of the Oncotype DX Breast Cancer Recurrence Score Test. The test’s adoption continued to expand in both Hong Kong and Macau. Supported by ongoing collaboration with the Hong Kong Breast Cancer Foundation, the Group further advanced public education on genomic testing and precision medicine, reinforcing Oncotype DX’s position as a trusted diagnostic assay test that provides individualised data on tumor biology , helping doctors tailor a treatment plan specifically to the individual, ensuring appropriate therapy and increasing confidence in treatment decisions.  Expanding E-Commerce and TCM Market OpportunitiesDuring the Reporting Period, the Group further expanded its presence across leading cross-border e-commerce platforms such as Tmall Global, JD.com, and Alibaba Health. Ho Chai Kung and Po Chai Pills continued to perform strongly online. These efforts enhanced brand awareness, customer perceptions and product acceptance amongst the target prospects in Chinese MainlandIn the traditional Chinese medicine (TCM) market, the Group maintained stable performance in its CCMG business, supplying over 700 single- and combo-formula granules to a wide network of registered practitioners. To capture new market opportunities, JBM Healthcare is expanding its TCM portfolio with new products and an upgraded e-business platform designed to streamline ordering processes, enhance practitioner engagement, and integrate online and offline service experiences.Mr. Derek Sum, Executive Director of JBM Healthcare, commented, “Amid a challenging market, we sustained growth through disciplined execution and the continued strength of our flagship brands. Our diversified portfolio and expanding e-commerce footprint have reinforced JBM Healthcare’s resilience and competitiveness. Looking ahead, we will continue to enrich our product mix, deepen customer engagement, and capture opportunities across Hong Kong, the Greater Bay Area, and other key markets to deliver sustainable long-term value.”About JBM (Healthcare) Limited (Stock Code: 2161)JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and other select countries. The Group is a distinctive player in the sector with marketing expertise and heritage in pharmaceuticals that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Tin Hee Tong Tin Hee Pills, Contractubex, Tong Tai Chung Woodlok Oil , Flying Eagle Woodlok Oil , Saplingtan , Shiling Oil and Konsodona Medicated Oil . JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hkFor media inquiries, please contact:Strategic Financial Relations LimitedVicky LeeTel: (852) 2864 4834Email: vicky.lee@sprg.com.hkRachel KoTel: (852) 2114 2370Email: rachel.ko@sprg.com.hkCoco YuTel: (852) 2864 4876Email: coco.yu@sprg.com.hk Fax: (852) 2527 1196 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

業績亮點- 收益按年增長7.7%至4.3億港元- 毛利上升23.2%至2.5億港元- 股東應佔溢利上升20.0%至1.15億港元- 宣派中期股息每股9.75港仙- 旗艦品牌何濟公及保濟丸在高效的市場推廣及品牌執行策略帶動下持續穩健增長- 跨境電商及中藥配方顆粒業務保持穩定，為整體表現作出貢獻香港, 2025年11月17日 - (亞太商訊 via SeaPRwire.com) - 健倍苗苗（保健）有限公司（「健倍苗苗」或「本公司」，股份代號：2161，連同其附屬公司統稱「集團」），作為香港領先的品牌保健產品市場推廣及分銷商，今日公佈截至二零二五年九月三十日止六個月（「二零二六財年中期」或「報告期」）之中期業績。儘管零售環境仍具挑戰，集團於報告期內錄得穩健增長，收益上升7.7%至4.3億港元，股東應佔溢利上升20.0%至1.15億港元。業績表現主要受惠於旗下旗艦自主品牌的持續動力、多元化產品組合以及嚴謹的執行力。集團繼續透過綜合市場推廣、電子商貿拓展及策略性互動合作，進一步強化品牌資產並擴展於香港及大灣區的市場覆蓋。業務板塊表現穩健報告期內，品牌藥業務錄得穩定增長，主要由於旗艦品牌何濟公的持續動力帶動。憑藉其作為家傳戶曉的止痛退燒良藥的信譽，品牌透過一系列具影響力的市場推廣活動強化市場地位。由品牌代言人張敬軒先生演出的電視廣告提升了品牌知名度與強化了消費者互動，而策略性的贊助與活動合作則擴大了受眾覆蓋範圍。該品牌亦通過贊助知名電視節目獲得了高度曝光，有效觸及中高齡與年輕消費者群體。品牌中藥業務表現同樣理想，由保濟丸的出色增長帶動，並受中藥配方顆粒業務的穩定貢獻支持。報告期內，保濟丸推出全新「條裝版」包裝，「一撕即食」，即撕開包裝便可服用，為消費者帶來便攜便利的新體驗。由古天樂先生帶領、加上胡子彤先生及黃正宜小姐演出的廣告，以輕鬆幽默的手法展現產品特色，融合懷舊與現代視覺美感，上線短短數周即錄得數百萬觀看次數，進一步鞏固品牌動力。品牌並透過校園互動活動、社區文化展覽及大型戶外廣告，加強跨世代的市場滲透及消費者共鳴。健康及保健產品業務錄得溫和下跌，主要由於對部分產品進行整合，但Oncotype DX乳癌復發基因檢測持續穩健增長，並抵銷部分跌幅。該檢測於香港及澳門的應用持續擴大。在與香港乳癌基金會的持續合作支持下，集團進一步推廣基因組檢測及精準醫療的公眾教育，鞏固Oncotype DX作為可靠診斷檢測的地位。此檢測能提供腫瘤生物學的個體化數據，協助醫生制定專屬的治療方案，確保患者獲得適切治療，並提升治療決策的信心。拓展電商版圖及中醫藥市場機遇報告期內，集團進一步擴展於跨境電商平台的佈局，包括天貓國際、京東及阿里健康等主要電商渠道。何濟公及保濟丸在線上渠道表現持續強勁。這些舉措有效提升了中國內地目標潛在客戶對品牌的認知度、好感度及對產品接受程度。於中醫藥市場方面，集團的中藥配方顆粒業務維持穩定表現，為香港超過700名註冊中醫師提供單方及複方顆粒產品，憑藉穩定品質與可靠供應獲業界廣泛信任。為進一步擴大市場覆蓋，集團正積極開發新產品並推出升級版電子商貿平台，以提升訂單流程效率、強化與中醫師及診所的互動，並整合線上線下服務體驗，推動業務長遠增長。健倍苗苗執行董事岑廣業先生表示：「在具挑戰的市場環境下，我們憑藉審慎執行力與品牌實力，持續錄得穩健增長。憑藉多元化的產品組合與日益擴大的電商版圖，我們的韌性與市場競爭力得到進一步提升。展望未來，我們將豐富產品組合、深化客戶互動，並把握香港及大灣區以至其他重點市場的機遇，為持份者締造可持續的長期價值。」有關健倍苗苗（保健）有限公司（股份代號：2161）健倍苗苗是設於香港的品牌醫療保健品推廣及分銷公司，產品據點遍及大中華、東南亞及其他選定國家。集團擁有豐富的行銷專業知識並具備深厚的製藥背景，秉承產品功效和品質至上的優良傳統，在行業內定位獨特，致力於滿足消費者的保健需要。作為本地領先的品牌醫療保健品運營商，集團擁有一廣泛系列品牌醫療保健品，包括品牌藥、品牌中藥及健康保健品，其中包括「保濟丸」、「何濟公止痛退熱散」、「天喜堂天喜丸」、「德國秀碧除疤膏」、「唐太宗活絡油」、「飛鷹活絡油」、「十靈丹」、「十靈油」及「鎮痛霸祛風活絡油」等家喻戶曉的傳統品牌。而自2021年5月27日，集團獲納入MSCI香港微型股指數成份股。有關集團詳情，請瀏覽：www.jbmhealthcare.com.hk傳媒查詢：縱橫財經公關顧問有限公司李惠兒電話:（852） 2864 4834電郵: vicky.lee@sprg.com.hk高文萱電話:（852） 2114 2370電郵: rachel.ko@sprg.com.hk余淑媛電話:（852） 2864 4876電郵: coco.yu@sprg.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAIPEI, TAIWAN, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) - OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology.Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization[1]. At present, there are no FDA approved ADC therapies for cholangiocarcinoma.To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to experimental therapies that have the potential to treat these diseases. In the United States, a rare disease is defined as any condition that affects fewer than 200,000 patients. After granting Orphan Drug Designation, the US FDA qualifies companies or drug developers incentives such as tax credits for clinical trials, exemption from user fees, and marketing exclusivity[2].In August 2025, OBI launched a phase I/II clinical trial in the United States and Taiwan, recruiting patients with advanced solid tumors. The objectives of the trial are to study the safety, pharmacokinetics, and preliminary efficacy profile of OBI-902 in these patient populations.Heidi Wang, Ph.D, OBI Pharma's Chief Executive Officer noted, "Based on our preclinical data, OBI-902 has several important advantages over other TROP2 ADCs either approved or in development; including high stability in blood circulation, excellent bystander effect that extends the killing to neighboring cancer cells lacking TROP2 expression, potential ability to overcome drug resistance, and outstanding activity in animal and organoid models of cancer. Importantly, this marks the first time an ADC that incorporates OBI's proprietary GlycOBI® ADC technology is being evaluated in patients, including those diagnosed with cholangiocarcinoma. We look forward to investigating this potential best-in-class TROP2 ADC in the clinic."About OBI-902OBI-902 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload to kill tumor cells and with a drug-antibody ratio (DAR) of 4. TROP2 is highly expressed in a variety of solid tumors such as breast, lung, biliary, bile duct (cholangiocarcinoma), ovarian, gastric, and many other cancer types, rendering it an ideal target for cancer therapy.OBI-902 is a novel site-specific glycan-conjugated ADC using OBI's proprietary GlycOBI platform, which provides improved stability and enhanced hydrophilicity. OBI-902 demonstrated remarkable antitumor efficacy, improved pharmacokinetic characteristics, and a favorable safety profile in various animal models. The IND of OBI-902 was cleared by the US FDA on April 30, 2025.Since December 2021, OBI has been granted by Biosion, Inc. (www.biosion.com) an exclusive, worldwide (except in China) license to a TROP2 targeting antibody amino acid sequence. Biosion holds exclusive rights to that antibody sequence in China. OBI holds worldwide commercial rights to OBI-902, except for the rights pertaining to the antibody in China.About GlycOBI®OBI has developed a unique clinical stage, glycan-based site-specific ADC technology (GlycOBI®), which is in a ‘Plug and Play' format and compatible with any antibodies, linkers, and payloads in drug-antibody ratio (DAR) up to 16. Utilizing OBI's proprietary dual-function enzyme (EndoSymeOBI®) and linker technology (HYPrOBI®), homogenous ADCs are manufactured with an efficient and scalable process under GMP conditions. The conjugation process of GlycOBI® avoids disrupting the antibody structure and ensures the ADC has similar biophysical characteristics to the native antibody. Furthermore, OBI's linker technology has improved conjugation efficiency of the payload, reduced aggregation propensity, which provides advantages on manufacturing ADC products. GlycOBI® conjugated ADCs have overcome the limitations of traditional ADCs and achieved better antitumor activity and stability in various in vivo animal studies. GlycOBI®, EndoSymeOBI®, and HYPrOBI® are part of the armamentarium of OBI's Obrion™ ADC Enabling Technologies that also include ThiOBI® and GlycOBI DUO™. OBI-902 is the first ADC utilizing OBI's Obrion™ ADC enabling technology for evaluation of safety and efficacy in Cancer, currently under Phase I/II clinical trial in the US and Taiwan.About OBI PharmaOBI is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission, together with its wholly owned subsidiary OBI Pharma USA, Inc., is to develop novel therapeutic agents for patients with high unmet medical needs.OBI's primary focus is the development of novel ADCs, including the first-generation cysteine-based TROP2 ADC, OBI-992. Using the company's proprietary ADC enabling technology, GlycOBI®, powered by EndoSymeOBI® and HYPrOBI®; OBI has created its next-generation novel ADC pipeline, including monospecific: OBI-902 (TROP2), OBI-904 (Nectin-4), bispecific single payload (HER2 x TROP2), and bispecific, dual payload (cMET x HER3) ADCs. To broaden the applicability of linker technology, HYPrOBI®, OBI further developed a novel ThiOBI® platform to enable irreversible cysteine-based conjugation. Additionally, OBI's pipeline includes the first-in-class AKR1C3-targeted small-molecule prodrug OBI-3424, which selectively releases a potent DNA-alkylating antitumor agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme that is highly expressed in tumors. Additional information can be found at www.obipharma.com.GlycOBI®, EndoSymeOBI®, ThiOBI® and HYPrOBI®are registered trademarks of OBI Pharma. Obrion™ and GlycOBI DUO™ are trademarks under registration.1 National Institute of Health for Rare Diseases. Sept. 2025https://rarediseases.info.nih.gov/diseases/9304/cholangiocarcinoma2 US FDA website. Designating an Orphan Product: Drugs and Biological Products Sept.25 https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-productsForward-Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau.COMPANY CONTACT:Kevin Poulos, Chief Business OfficerOBI Pharma USA, Inc.+1 (619) 537 7698, ext. 102kpoulos@obipharma.comSOURCE: OBI Pharma USA, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

JAKARTA, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) - Indonesia's state-owned social security agency PT TASPEN (Persero) has reiterated its commitment to ensuring social protection for all Indonesian Civil Servants and State Officials, including those stationed abroad.President Director Taspen, Rony Hanityo (2nd left) delivers Work Accident Security Program benefits to the wife of the late Zetro Leonardo Purba, Junior Chancellery Officer at the Indonesian Embassy in Lima, Peru, who died while performing official duties on Sept 1, 2025.The statement follows TASPEN's recent distribution of Work Accident Security Program (Jaminan Kecelakaan Kerja/JKK) benefits to the family of the late Zetro Leonardo Purba, a Junior Chancellery Officer at the Indonesian Embassy in Lima, Peru, who died while performing official duties on September 1, 2025.TASPEN Corporate Secretary Henra expressed condolences to the bereaved family and underscored the agency's role in upholding the state's responsibility to protect civil servants serving anywhere in the world."TASPEN expresses its deepest condolences on the passing of Mr. Zetro Leonardo. The distribution of these benefits is proof that TASPEN carries out its state mandate with integrity and accountability. It is our responsibility to ensure that every civil servant's dedication — even at the farthest corners of the world — is accompanied by a sense of security for them and their families. The state's protection knows no borders," said Aprianto.As of September 30, 2025, TASPEN has provided JKK benefits to 221 heirs of Indonesian civil servants, including those serving on overseas assignments — a reflection of the government's continued commitment to the welfare of public sector workers worldwide.Comprehensive Protection for Civil Servants and FamiliesThe assistance provided to Mr. Purba's family includes Old-Age Savings Program (Tabungan Hari Tua/THT) and Work Accident Security Program benefits, such as Death Benefits/Bereavement Benefits, Death Compensation, and Funeral Benefit. In addition, Scholarship Benefit has been granted for two of his children to support their continued education — part of TASPEN's broader effort to ensure long-term family welfare.The Work Accident Security Program (JKK) forms part of Indonesia's national social protection framework for civil servants and state officials who experience work-related accidents, occupational illnesses, or death while performing state duties — whether domestically or abroad.Four Key Programs Supporting Civil ServantsTASPEN manages four major programs designed to create an integrated and sustainable social security system for civil servants:1. Old-Age Savings Program (THT): A savings and protection plan for employees nearing retirement or their families in case of death before retirement.2. Pension Program: Guarantees a regular post-retirement income as recognition of civil servants' long-term service.3. Work Accident Security Program (JKK): Covers the risk of workplace injuries, illnesses, or death occurring in the line of duty, including while serving abroad.4. Death Security Program (Jaminan Kematian/JKM): Provides compensation and educational scholarships for the families of civil servants who pass away from non-work-related causes.These programs establish a comprehensive social safety net that protects civil servants throughout their professional and personal lives. TASPEN's initiatives reflect the Indonesian government's principle that public service deserves lifelong protection — regardless of where it is carried out. By extending coverage beyond national boundaries, the TASPEN ensures that Indonesian civil servants serving on global missions receive the same level of welfare assurance as those at home.Through adaptive and accountable management, TASPEN continues to play a strategic role as a partner of the Indonesian government in strengthening the welfare and security of civil servants worldwide.About PT TASPEN (Persero)PT TASPEN (Persero) or the Civil Servant Savings and Insurance Fund is an Indonesian state-owned enterprise engaged in retirement savings insurance and pension funds for civil servants (ASN) and state officials. Established on April 17, 1963, PT TASPEN (Persero) plays an active role in social welfare, particularly for civil servants in Indonesia. PT TASPEN (Persero) currently offers several products and services, namely the Work Accident Security Program (JKK), Death Security Program (JKM), Old-Age Savings Program (THT), and Pension Program.PT TASPEN (Persero) is currently the First Chairman of the Asian Civil Service Pension Association (ACSPA), which is the first Association of Social Security Administrators for Civil Servants in Asia, with members consisting of Social Security Administrators for ASN from various countries in Asia, including Indonesia, South Korea, the Philippines, Thailand, and Cambodia. PT TASPEN (Persero) prioritizes the comfort and safety of its participants by implementing the digital superapp service Andal by TASPEN.For information, you can contact the Call Center at 1500919, visit the official website www.taspen.co.id, tcare.taspen.co.id, and all official social media accounts of PT TASPEN (Persero). Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

台北，台灣, 2025年11月17日 - (亞太商訊 via SeaPRwire.com) - 台灣浩鼎（4174.TWO）今（11/16）日宣布，接獲美國食品藥物管理局（US FDA）通知，旗下以 TROP2 為靶向的ADC新藥 OBI-902 ，已獲審核通過治療膽管癌（Cholangiocarcinoma）的「孤兒藥（Orphan Drug Designation）」資格認定。OBI-902 為浩鼎首款自主開發、採用醣位點專一性鍵結的新型 ADC。膽管癌是一種罕見且致死率高的惡性腫瘤，美國患者人數少於五萬人。依疾病分期、組織型態及發病部位不同，其五年存活率約介於2%至23%¹。目前，美國 FDA 尚未核准針對膽管癌的ADC藥物上市銷售。為鼓勵業界開發治療罕見疾病的新藥，美國 FDA 設有「孤兒藥」資格認定制度，凡具潛力的候選藥物經審核通過後即可獲得此資格認定。在美國，罕見疾病被定義為患者人數少於二十萬人的疾病。經美國 FDA 認定為「孤兒藥」後，藥物開發公司可獲得多項優惠措施，包括臨床支出稅務優惠、藥證申請費用減免，以及市場專賣保護期等²。                              浩鼎已於2025年8月在美國與台灣展開 OBI-902 一期/二期臨床試驗，招募晚期實體腫瘤患者。該試驗的目標在於驗證 OBI-902 的安全性、藥物動力學特性及初步療效。浩鼎執行長王慧君博士表示：「根據臨床前數據，OBI-902 相較於已上市或研發中的其他 TROP2 ADC，展現許多優勢，在血液循環中具高度穩定性、能對周圍未表現 TROP2 的癌細胞產生殺傷作用（旁觀者效應），同時具能克服抗藥性的潛力，在動物試驗和類器官癌症模型中，均顯現了出色的藥物活性。更重要的是，這是浩鼎首度在臨床上應用獨家專利的 GlycOBI® ADC 關鍵技術，其中包含膽管癌病人。我們期待以臨床試驗進一步證明： OBI-902成為同類最佳（best-in-class）的潛力。」About OBI-902OBI-902 是以 TROP2 為靶向的抗體藥物複合體（ADC）新藥，攜帶強效的拓撲異構酶 I 抑制劑以殺死腫瘤細胞，藥物抗體比例（Drug-Antibody Ratio, DAR）為 4。TROP2 在包括乳癌、肺癌、膽道癌（膽管癌）、卵巢癌、胃癌等多種實體瘤中均有高度表現，因而被視為癌症治療的理想靶點。OBI-902 是一款新型的醣位點專一性 ADC，採用浩鼎專利的 GlycOBI® 技術所驅動，具有良好的穩定性和親水性。在多種動物模型中，OBI-902 展現出卓越的抗腫瘤功效、出色的藥物動力學特性以及良好的安全性。其臨床試驗申請（IND）已於2025年4月30日獲美國 FDA 核准。本公司於2021年12月自博奧信生物技術公司（Biosion, Inc., www.biosion.com）授權引進 TROP2 抗體。依合約條款，博奧信保留該抗體在中國的相關權利，浩鼎則獲授權於中國以外的權利。除中國境內的抗體權利外，浩鼎擁有 OBI-902 ADC的全球商業化權利。About GlycOBI ®浩鼎開發出獨家專利的醣位點專一性ADC技術（GlycOBI®）已應用於臨床階段，其具備「隨插即用」特性，可與各類抗體、連接子（linkers）和藥物（payloads）兼容，藥物抗體比（Drug-Antibody Ratio, DAR）最高可達 16。透過自主研發的雙功能酵素 EndoSymeOBI® 與高親水性連接子技術 HYPrOBI®，可在 GMP 製程中高效率量產具均質性的 ADC。其偶聯過程避免了破壞抗體結構，並確保 ADC 具有與天然抗體相似的生物特性。另一方面，HYPrOBI® 高親水性連接子技術提升了藥物偶聯效率並降低藥物生產時不均勻結塊的風險，在 ADC 產品製程方面更具優勢。經多項動物實驗模型顯示，採用 GlycOBI® 偶聯的 ADC 在抗腫瘤活性與穩定性上優於傳統 ADC。GlycOBI®、EndoSymeOBI® 與 HYPrOBI® 為浩鼎 Obrion™ ADC 專利技術組合的一部分，另包含 ThiOBI® 與 GlycOBI DUO™。OBI-902 為首款採用浩鼎 Obrion™ ADC 關鍵技術進入臨床評估之新藥，目前已在美國與台灣進行一期/二期臨床試驗，以評估其在癌症治療中的安全性與療效。About OBI Pharma浩鼎成立於2002年，為產品已進展至臨床階段的全球癌症新藥開發公司，總部設於台灣。浩鼎與其全資子公司 OBI Pharma USA, Inc. 的使命，是致力於開發新型抗癌藥物，為具有高度醫療需求、尚未被滿足的患者提供新的治療選擇。浩鼎的研發核心聚焦於新型抗體藥物複合體（Antibody-Drug Conjugates, ADC），包括第一代半胱胺酸鍵結 TROP2 ADC OBI-992。透過專利的 ADC 關鍵技術 GlycOBI®，並結合 EndoSymeOBI® 與 HYPrOBI®，浩鼎已建立次世代 ADC 產品線，其中包含單抗 ADC：OBI-902（TROP2）、OBI-904（Nectin-4）；雙抗單藥 ADC：HER2 x TROP2；以及雙抗雙藥 ADC：cMET x HER3。為拓展 HYPrOBI® 連接子技術的應用範圍，浩鼎進一步開發新型 ThiOBI® 平台，以實現不可逆的半胱胺酸鍵結。此外，浩鼎的產品線亦包括全球首創 AKR1C3 靶向小分子前驅藥 OBI-3424，該藥物在腫瘤中高度表達的醛酮還原酶（AKR1C3）作用下，選擇性釋放強效 DNA 烷基化劑以治療癌症。更多資訊請參閱：www.obipharma.com。GlycOBI®、EndoSymeOBI®、ThiOBI® 與 HYPrOBI® 為浩鼎的註冊商標。Obrion™ 與 GlycOBI DUO™ 為申請中之商標。1 National Institute of Health for Rare Diseases. Sept. 2025https://rarediseases.info.nih.gov/diseases/9304/cholangiocarcinoma2 US FDA website. Designating an Orphan Product: Drugs and Biological Products Sept.25 https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products新聞聯絡：陳祈宏 Derek Chen公共事務處 主管| Head of Public Affairs台灣浩鼎（OBI Pharma, Inc.）M: +886-939-797-803 |T: +886-2-2655-8799 Ext. 223derekchen@obipharma.com Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- The 15th Asian Logistics, Maritime and Aviation Conference (ALMAC) opened today under the theme “Collaboration and Growth in the New Trade Landscape”- The event brings together over 80 heavyweight speakers to explore industry trends and opportunities, driving high-quality development in logistics and supply chain management-  New thematic sessions spotlight the Middle East and Central Asia markets, with speakers sharing the latest developments and future opportunities, analysing key strategies and investment directions- John Lee, Chief Executive of the HKSAR, and Almaz Turgunbaev, Deputy Minister of Transport and Communications of the Kyrgyz Republic, attended the Special Address session on the first day of the conference. Their participation aims to deepen international exchange and cooperation, helping to further enhance Hong Kong’s position as an international shipping and aviation hub and its roles as a “superconnector” and “super value-adder”.HONG KONG, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) – The 15th Asian Logistics, Maritime and Aviation Conference (ALMAC), organised by the Hong Kong Special Administrative Region (HKSAR) Government and the Hong Kong Trade Development Council (HKTDC), opened today (17 November) and runs for two days at the Hong Kong Convention and Exhibition Centre. Under the theme “Collaboration and Growth in the New Trade Landscape”, the conference aligns with recommendations in the 15th Five-Year Plan to enhance Hong Kong’s status as an international shipping centre, and policies laid out in the Policy Address to strengthen the development of the shipping, aviation and logistics sectors in the city. As the industry’s annual flagship event, the two-day conference gathers over 80 distinguished speakers, including government officials and industry leaders, to discuss trends and opportunities and promote high-quality development in logistics and supply chain management.John Lee, Chief Executive of the HKSAR, attended the first day of the conference to deliver a Special Address. In addition, this year’s ALMAC invited Central Asian official Almaz Turgunbaev, Deputy Minister of Transport and Communications of the Kyrgyz Republic, to also deliver a Special Address.John Lee said: “The conference theme this year, ‘Collaboration and Growth in the New Trade Landscape’, is a timely response to rising geopolitical tensions and the volatile global trade policies, which present considerable challenges for our maritime, aviation and logistics industries, from route planning and shipping fleet deployment to inventory and warehouse management. Nevertheless, as the Chinese saying goes, ‘where there are challenges, there are opportunities’. Geopolitical risks can be overcome by market diversification. Increased costs related to supply chain concerns can be offset, at least partially, by technology-enabled efficiencies.”Mr Lee also shared: “I am particularly pleased to announce that Hong Kong has established Partner Port relationships with Guangxi port and Dalian port in the Chinese Mainland, and Port San Antonio in Chile. These ports are of strategic importance, and true to our character and policy priorities. As an international maritime centre, we connect the Chinese Mainland with the world and seek partners who support an open, international trade order.”In her welcome remarks, Sophia Chong, Executive Director of the HKTDC, said: “Now is the perfect time to embrace new possibilities, as trade networks and supply chains around the world undergo a sweeping transformation. The ever-changing trade polices of major economies continue to keep business agile. At the same time, the world is being rapidly reshaped by technological advances – particularly the digitalisation of trade – and a growing industry-wide commitment to sustainability.  Hong Kong, as a major hub for aviation, shipping, logistics and supply chain management, is at the forefront of these changes. The HKTDC remains committed to leveraging the city’s unique strengths to help businesses establish resilient and sustainable supply chains, while reinforcing Hong Kong’s role as a superconnector and super value-adder.”Strengthening Hong Kong’s logistics hub role and promoting regional cooperationRecommendations in the 15th Five-Year Plan to support the consolidation and enhancement of Hong Kong’s status as an international shipping centre carry profound strategic significance. The HKTDC will continue to deepen Hong Kong’s role as an international exchange platform, facilitating connections and substantive cooperation between local and overseas industries, assisting enterprises in “going global”, helping to expand their businesses in global markets, and enhancing their competitiveness. A key focus is promoting trade linkages and actively encouraging enterprises to leverage the HKTDC’s trade platforms and events to achieve greater cooperation across industries. This year’s ALMAC continues to feature business-matching sessions, connecting shippers with service providers to foster regional partnerships and drive industry growth.ALMAC this year features exhibition zones dedicated to aviation, the low-altitude economy, technology, supply chain management and logistics services as well as maritime and port services. Over 90 exhibitors are showcasing the latest leading logistics and supply chain solutions. Notably, the Low-altitude Economy zone makes its debut at ALMAC, with enterprises from the Regulatory Sandbox pilot projects – including SF Express (Hong Kong) and Esri China (Hong Kong) Limited –demonstrating cutting-edge technologies and applications in drones, unmanned aerial vehicles (UAVs) and urban air mobility (UAM), promoting awareness of the latest innovations and applications in this fast-rising sector.Three key trends in focus; unlocking opportunities in the Middle East and Central AsiaThis year’s ALMAC focuses on three key trends: supply chain diversification, sustainability and green energy and innovation and technology, highlighting Hong Kong’s critical role in global connectivity.On the first day, the key session “Insights into a New Era of Global Trade: Driving Business Growth” will feature international industry leaders from SEKO Logistics, GEODIS, and Mattel who will explore the challenges and opportunities arising from changes in trade policies and economic fragmentation. Newly launched thematic sessions will focus on the potential of the Middle Eastern and Central Asian markets. In the Middle East Session, representatives from Etihad Airways, DP World Logistics and the Qatar Free Zones Authority will share insights on logistics innovation and investment strategies. The Central Asia Session will engage representatives from QazTrade Center for Trade Policy Development, JSC, under the Ministry of Trade and Integration of the Republic of Kazakhstan, Shyngar Trans Logistics Company, the Organisation for Economic Co-Operation and Development and PTC. The discussion will address regional supply chain development and the advantages of multimodal transport.Low-altitude economy and smart ports: reshaping the air and maritime transport landscapeIn the first-day session “The Engine of Low-altitude Economy: How Cargo Drones Are Revolutionising the Future of Air Logistics”, Manal Habib, CEO and Founder, MightyFly; Bobby Healy, CEO and Founder, Manna; Kenny Lau, Chief Technology Officer, SF Express (Hong Kong) Limited; Ryan Walsh, Founder and CEO, Valqari; and Andrea Wu, CEO, Urban-Air Port Ltd, shared the latest breakthroughs in drone freight design, automation and AI-driven logistics systems. Meanwhile, the Low-altitude Economy zone at the conference is showcasing drones and related applications, allowing participants to experience first hand the future of air transport and explore the potential of low-altitude economy innovations in the logistics sector.In addition, the Port Community System X LSCM Maritime Summit 2025 will focus on the future development of smart ports and smart trade. The summit will explore how applying the Port Community System (PCS) can significantly enhance operational efficiency and supply chain visibility through cutting-edge technologies such as AI, blockchain and the Internet of Things. It will also showcase Hong Kong’s unique advantages as an international shipping centre and a hub for smart trade. Conference and workshops support enterprises’ green transformationA first-day workshop, “Sustainable Finance: Navigating a Sustainable Future across Logistics, Shipping, and Aviation Industries”, focused on how ESG (environmental, social and governance) is reshaping operational models and development directions in the logistics, maritime and aviation sectors. Patrick Lau, Deputy Executive Director of the HKTDC, gave the Opening Address at the workshop, followed by industry experts including KT Ting, Chief Operating Officer, Hong Kong Quality Assurance Agency; Calvin Chung, Director, Chimbusco Pan Nation; Wai Yeung Tam, Senior Finance Manager, SF REIT Asset Management Limited; and Eric Liu, Chief Executive, Cathay United Bank Hong Kong Branch. They discussed challenges and opportunities in the industry’s green transformation and addressed the important role of sustainable finance to support enterprises in the transition.As the world strives towards net-zero emissions, Hong Kong is committed to developing as a green maritime centre. The recent Policy Address proposes establishing Hong Kong as a green marine fuel bunkering centre, focusing on green methanol, green ammonia and hydrogen. A session titled “Green Energy Forum: Fuels, Freight, and the Road to Net Zero” will be held tomorrow (18 November) to share pathways, challenges and opportunities for a more sustainable and low-carbon future. Speakers include Essam Al Sheibany, Vice President Sustainability, Asyad Group; Tryggvi Thor Herbertsson, Head of Hydrogen Strategy and Partnership, Qair Group; James Laybourn, Regional Segment Director, APAC, DNV Energy Systems; and Wu Yi, Deputy General Manager, Kunlun Energy Co., Ltd.ALMAC offers a rich and diverse programme for participants, with tomorrow’s highlighted sessions, including the Hong Kong Authorized Economic Operator (AEO) Programme, the Supply Chain Management and Logistics Panel, “Logtech Forum: Stay Ahead in the Next Wave of Supply Chain Innovation”, and the Youth Empowerment Workshop. Representatives from companies such as HP, Reckitt, DHL Express, LALAMOVE and Procter & Gamble will share valuable insights and practical skills, helping participants stay ahead of the latest industry developments.The 15th Asian Logistics, Maritime and Aviation ConferenceDate17 and 18 November 2025 (Monday and Tuesday)VenueHall 3FG, HKCECWebsitesALMAC: https://almac.hktdc.com/conference/almac/enProgramme: https://almac.hktdc.com/conference/almac/en/programmeSpeaker list: https://almac.hktdc.com/conference/almac/en/speakerPhoto download: https://bit.ly/4ojiKsFThe 15th Asian Logistics, Maritime and Aviation Conference (ALMAC), organised by the HKSAR Government and the HKTDC, opened today. Under the theme “Collaboration and Growth in the New Trade Landscape”, the event brings over 80 heavyweight speakers to explore industry trends and opportunitiesJohn Lee, Chief Executive of the HKSAR, attended the first day of the conference to deliver a Special AddressSophia Chong, Executive Director of the HKTDC, delivered welcome remarks at the Opening SessionBusiness-matching sessions at ALMAC are connecting shippers with service providers to foster regional partnerships and drive industry growthThe Low-altitude Economy zone made its debut at this year’s ALMAC Exhibition, demonstrating cutting-edge technologies and applications in drones, unmanned aerial vehicles and urban air mobilityThe session titled “Steering Business Growth in a New Era of Global Trade” explored the ripple effects of evolving trade policies and the impact of rising economic fragmentationIn the session “Tapping the Middle East: Logistics, Innovation & Trade Potentials”, industry leaders from the Middle East shared the huge opportunities and transformation potential in logistics and supply chainsMedia enquiriesYuan Tung Financial Relations:Louise SongTel: (852) 3428 5690Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Johnny TsuiTel: (852) 2584 4395Email: johnny.cy.tsui@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

The updated study incorporates redesigned dry-stack tailings system engineered to eliminate acid mine drainage and is one of the final ESIA reports.Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - November 17, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects, is pleased to announce that it has commissioned an updated Air Dispersion Modelling and Dust Management Study (the "Study") for its 100%-wholly owned Lac Knife Project (the "Project") in Quebec. This work represents one of the final environmental studies required to complete the Environmental and Social Impact Assessment ("ESIA") and advance the Project toward mine-permitting readiness.The Study will be led by WSP Canada Inc. ("WSP"), a world-leading Montreal-based global engineering, environmental, and professional-services consultancy, and will be conducted under the supervision and management of IOS Geosciences Inc. ("IOS"), the Company's geological consultant and general contractor for the Project. WSP includes the former Woods Engineering, which participated in the 2019 preliminary design of the dry-stack tailings storage facility ("TSF"), as well as Golder Inc., which conducted the original 2014 Study.The Study will evaluate the potential airborne dispersion of dust and gases associated with mining operations, including:wind-driven erosion from the TSF,emissions generated by blasting activities, andtraffic-related dust along the 7-kilometre access road linking Lac Knife to Highway 389.This updated modelling replaces the earlier 2014 study to reflect the re-engineered dry-stack tailings design, developed as part of the 2021 Feasibility Study (the "Feasibility") update. The redesign eliminates the former wet-pond configuration and instead utilizes dolomitic marble to amend and encapsulate tailings, thereby preventing acid mind drainage ("AMD") and metal leaching. This new TSF concept was considered material enough to necessitate remodelling of the areal dispersion.The current program directly addresses follow-up questions from Quebec's Ministry of Sustainable Development, Environment, and the Fight Against Climate Change ("MDDELCC"), issued during its review of the Company's 2014 ESIA submission. Results from the Study are expected by February 2026, aligning with the planned submission of the final revised ESIA."The completion of the air dispersion modelling and dust management plan marks one of the last major technical steps in our environmental review process," said Dean Hanisch, Chief Executive Officer of Focus Graphite. "We are now systematically finalizing outstanding ESIA components to move Lac Knife toward the permitting stage. Each of these studies reflects our ongoing commitment to advance the Project responsibly."Qualified PersonThe technical content disclosed in this news release was reviewed and approved by Rejean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About WSP Canada Inc.WSP Canada Inc. is a Canadian subsidiary of WSP Global Inc., one of the world's leading professional-services firms. Headquartered in Montreal, Quebec, WSP provides multidisciplinary engineering, environmental, and consulting services across the infrastructure, energy, mining, transportation, and built-environment sectors. With thousands of professionals across Canada and internationally, WSP delivers technical excellence and sustainable solutions supporting clients through every stage of project development.For more information on WSP Canada Inc. please visit https://www.wsp.com/en-ca/ About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Focus Graphite's flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Focus Graphite's Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, they go beyond mining – we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Focus Graphite's commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals – reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comLinkedIn: https://www.linkedin.com/company/focus-graphite/ X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated timing, scope, and results of the Air Dispersion Modelling and Dust Management Study (the "Study") at the Lac Knife Project; the completion of the Company's Environmental and Social Impact Assessment ("ESIA") and related technical studies, including hydrogeological and tailings dam analyses; the expected timing of regulatory submissions and approvals; the potential for the Project to achieve mine-permitting readiness; and the advancement of the Lac Knife Project toward development. Forward-looking information also includes statements regarding the Company's expectations concerning the effectiveness of the redesigned dry-stack tailings storage facility, the ability to meet Québec's environmental and regulatory standards, the anticipated role of the Lac Knife and Lac Tetepisca projects within Canada's Critical Minerals Strategy, and the Company's capacity to secure the financing and partnerships required to advance these projects responsibly and sustainably.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274738 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Nov 17, 2025 - (ACN Newswire via SeaPRwire.com) – iRad Hospital, the pioneering resort medical facility located at Studio City, today announced the signing of a cooperation agreement with Hong Kong Sanatorium & Hospital. This partnership launches comprehensive cross-border medical concierge services, reinforcing the Macau government's "1+4" moderate economic diversification framework and supporting Macau's emergence as a medical tourism destination.This strategic alliance enables seamless connectivity of medical services between the two regions, providing patients with access to expanded specialty medical resources through iRad's medical concierge platform.Combining Hong Kong Sanatorium & Hospital's 103-year legacy of comprehensive medical excellence with iRad's over 20 years of professional medical experience and resort-integrated healthcare model, this partnership establishes an unprecedented healthcare network covering the Pearl River Delta region.The medical concierge program facilitates integrated care coordination, efficient cross-institutional scheduling, and personalized treatment plans utilizing resources from both institutions. This comprehensive approach ensures seamless continuity of care, delivering better clinical outcomes for patients seeking medical services in the region.Mr. Lawrence Ho, Founder of Black Spade Capital and Chairman & CEO of Melco, stated, "The collaboration between iRad and Hong Kong Sanatorium & Hospital demonstrates our commitment to advancing Macau's '1+4' industrial transformation agenda, creating vital healthcare connections between the two regions, enriching Studio City's health tourism offerings while expanding healthcare options for the Greater Bay Area community."Mr. Wyman Li, Chief Operating Officer of HKSH Medical Group, remarked, "Partnering with iRad reflects our vision of borderless healthcare, bringing exceptional value to patients in both markets, developing new approaches for the Greater Bay Area, and further deepening collaborative innovation across various sectors within the region."Photo caption: (From left to right) HKSH Head of Business Development Mr. Wei-Hsu Chen, iRad Hospital Founder & Chairman Dr. Matthew Ngan, HKSH Medical Group Chief Operating Officer Mr. Wyman Li, Black Spade Capital Founder and Melco Chairman & CEO Mr. Lawrence Ho, Black Spade Capital CEO and iRad Hospital Honorary Chairman Mr. Dennis Tam, HKSH Assistant Medical Superintendent Dr. Lau Chor Chiu, and iRad Hospital CEO Mr. Kin Wong celebrate the strategic partnership between iRad Hospital and Hong Kong Sanatorium & Hospital.About HKSH Medical GroupOfficially launched in September 2017, HKSH Medical Group promotes public health and advanced medicine through a multi-faceted, coordinated approach across clinical services, medical education, scientific research and public health education. Members of the Group, including Hong Kong Sanatorium & Hospital, HKSH Healthcare and HKSH Eastern Medical Centre, are dedicated to offering top-quality holistic care to patients, upholding the motto “Quality in Service, Excellence in Care.”Hong Kong Sanatorium & Hospital is a key member of HKSH Medical Group. Established in 1922, it is one of the leading private hospitals in Hong Kong. Living up to its motto of “Quality in Service Excellence in Care,” the Hospital is committed to serving the public as well as promoting medical education and research.For more information about HKSH Medical Group, please visit www.hksh.com.About iRad Medical Group—Hong Kong's Largest MRI Diagnostic Service ProviderEstablished in 2005, iRad is a trusted leader in diagnostic radiology across Hong Kong. Black Spade Capital has been iRad Medical's controlling shareholder since 2021. As at 2024, iRad was the largest MRI diagnostic services provider in Hong Kong by revenue and by the number of MRI scanners. Focused on delivering high-quality imaging services and exceptional patient care, the Group's strong and extensive client base includes the Government of the Hong Kong SAR, as well as other high-profile medical groups, corporations, private doctors and NGOs. Meanwhile, iRad Hospital is the first and largest private medical imaging and examination service provider within an integrated resort in Macau, making iRad Group the first medical imaging group in the world to offer comprehensive private imaging and examination services, including MRI and CT services, to the integrated resort industry.Media Enquiries:Strategic Financial Relations LimitedVicky LeeTel: +852 2864 4834Email: vicky.lee@sprg.com.hk Iris Au YeungTel: +852 2114 4913Email: iris.auyeung@sprg.com.hkWebsite: www.sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年11月17日 - (亞太商訊 via SeaPRwire.com) - 位於新濠影滙的開創性度假村醫療設施卓智醫院（iRad），今日宣布與香港養和醫院簽訂合作協議。此次合作推出全方位跨境醫療禮賓服務，強化澳門政府「1+4」產業適度多元發展框架，助力澳門成為新興醫療旅遊目的地。這項戰略聯盟實現兩地醫療服務的無縫連接，透過iRad的醫療禮賓平台為患者提供更多專科醫療資源。結合香港養和醫院103年深厚的綜合醫療傳承與iRad逾20年的專業醫療經驗及度假村融合醫療模式，此夥伴關係建立起覆蓋珠江三角洲地區前所未有的醫療網絡。醫療禮賓計劃促進綜合護理協調、跨機構高效排程，以及運用雙方機構資源制定的個人化治療方案。這種全面的方式確保護理服務的無縫銜接，為區內尋求醫療服務的患者帶來更佳的臨床效果。黑桃資本創辦人及新濠主席兼行政總裁何猷龍先生表示：「iRad與香港養和醫院的合作展現我們推進澳門『1+4』產業轉型議程的承諾，在兩地之間創建重要的醫療連結，豐富新濠影滙的健康旅遊內容，同時擴展大灣區社區的醫療選擇。」養和醫療集團營運總監李維文先生表示：「與iRad合作反映我們無界限醫療的願景，為兩地市場的患者帶來卓越價值，為大灣區發展新思路，進一步深化灣區內各領域間合作創新。」圖片說明：（左起）香港養和醫院業務拓展主管陳威旭先生、卓智醫院創辦人兼主席顏文煌醫生、養和醫療集團營運總監李維文先生、黑桃資本創辦人及新濠主席兼行政總裁何猷龍先生、黑桃資本行政總裁及卓智醫院榮譽主席譚志偉先生、香港養和醫院副院長劉楚釗醫生，以及卓智醫院首席執行官黃建豐先生，共同慶祝卓智醫院與香港養和醫院達成戰略夥伴關係。關於養和醫療集團養和醫療集團於 2017 年 9 月正式啟動，旗下成員分別有養和醫院、養和醫健、養和東區醫療中心及養和癌症中心。養和醫療集團以全方位策略，透過優質臨床醫療服務、醫學教育和科研，以及公眾健康教育，推動公共衞生及醫學發展，致力為患者提供全人關顧的優質醫療及護理服務。養和醫院是養和醫療集團之重要成員，成立於 1922 年，為香港主要私營醫院之一，以「優質服務‧卓越護理」為宗旨，致力服務大眾，並積極推動醫學教育和研究。關於養和醫療集團，請瀏覽www.hksh.com.關於卓智醫療集團—香港最大的磁力共振診斷服務供應商卓智醫療成立於2005年，是香港放射診斷領域規模領先的醫療集團。黑桃資本自2021年起成為卓智醫療的控股股東。截至2024年，卓智醫療集團憑藉營業收入及磁力共振掃描儀數量，成為香港規模最大的磁力共振診斷服務供應商。集團致力提供優質的醫學掃描診斷服務及卓越的病人護理，擁有廣泛且穩固的客戶基礎，包括香港特別行政區政府、知名保險公司、具影響力的醫療團體、企業、私人醫生和非政府組織。與此同時，卓智醫院作為澳門綜合度假村內首家且規模最大的私人醫學影像與檢查服務供應商，使卓智集團成為全球首個為綜合度假村產業提供全面私人影像及檢查服務（包括磁力共振與電腦斷層掃描服務）的醫學影像集團。傳媒垂詢：縱橫財經公關顧問有限公司李惠兒電話：+852 2864 4834電郵：vicky.lee@sprg.com.hk 歐陽蔚雯電話：+852 2114 4913電郵：iris.auyeung@sprg.com.hk網址：www.sprg.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com